Oral Presentation Australian and New Zealand Stroke Organisation Conference 2026

Management of systolic blood pressure during endovascular thrombectomy under general anaesthesia for acute ischaemic stroke (MASTERSTROKE)  (138379)

Doug Campbell 1 , Davina S McAllister 1 , William K Diprose 2 3 , David Highton 4 , Christopher Frampton 5 , Fiona McBryde 3 , Timothy Short 1 , Alan Barber 3
  1. Auckland City Hosptial, Auckland
  2. John Hunter Hospital, Newcastle, Australia
  3. University of Auckland, Auckland, NZ, New Zealand
  4. Princess Alexandra Hospital, Brisbane
  5. University of Otago, Christchurch

Background  Cerebral autoregulation is impaired in patients with large vessel occlusion (LVO) ischaemic stroke. Guidelines suggest intraprocedural systolic blood pressure (SBP) targets of 140-180 mmHg during endovascular thrombectomy (EVT). Higher SBP may increase penumbral blood flow, reduce infarct size and improve functional recovery, whereas lower SBP may reduce haemorrhagic transformation.

Methods   MASTERSTROKE was a double-blind, randomised-controlled trial of anterior circulation LVO patients having EVT under general anaesthesia. Participants were randomised (1:1) to treatment arms of intra-procedural SBP 140±10 mmHg or 170±10 mmHg. The primary efficacy outcome was shift in modified Rankin Scale score (mRS) at day-90.

Results   There were 562 patients (287 [51.0%] female, mean [SD] age 69.6 [14.5] years, baseline median [IQR] NIHSS 15 [11-20]); 280 randomised to the 140 mmHg and 282 to 170 mmHg treatment groups, respectively. Median achieved intra-procedural SBP was 141 (135-148) and 170 (162-177) mmHg. Day-90 median mRS score was 2 (1–4) in both groups (P=0.49). The proportion of participants with good functional recovery (mRS 0-2) was 54.9% and 51.1%, (OR 1.30 [95% CI, 0.80 to 2.11]; =0.33). Symptomatic intracranial haemorrhage occurred in 2.1% and 2.1% (OR 0.99 [95% CI, 0.32-3.12]) and all-cause day-90 mortality was 12.1% and 15.2% (OR 0.87 [95% CI, 0.62-1.21]; P=0.28).

Conclusion  This large multicentre trial is the first to test and achieve specific SBP targets during EVT. We provide class 1 evidence that there is no signal of additional benefit or harm across the 140-180 mmHg range of intra-procedural SBP recommended in current guidelines.